Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649857 | Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg | PHASE1 | COMPLETED | 18 | — | — | Nov 1, 2002 | Dec 1, 2002 | Apr 24, 2024 | 1 | United States |
| NCT00650065 | Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg | PHASE1 | COMPLETED | 26 | — | — | Nov 1, 2002 | Dec 1, 2002 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cetirizine HCl Tablets 10 mg |
| 2 | ACTIVE_COMPARATOR | Zyrtec® 10 mg |
| Name | Type | Description |
|---|---|---|
| Cetirizine HCl Tablets 10 mg | DRUG | 10mg, single dose fed |
| Zyrtec® 10 mg | DRUG | 10mg, single dose fed |
| Zyrtec® Tablets 10 mg | DRUG | 10mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...